NCT04163718 2026-01-06
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
Clinical Trials
5 trialsNCT04508647 2024-03-21
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
University of Colorado, Denver
Phase 2 Completed
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03776864 2023-05-03
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
University of Washington
Phase 2 Terminated
NCT03178201 2021-07-16
TGR1202 in Relapsed and Refractory Follicular Lymphoma
Columbia University
Phase 2 Terminated